Plain-English translation of NCT07108036 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 trial testing a medication called Anktiva (nogapendekin alfa inbakicept) in people with long COVID. The study will evaluate whether the medication is safe and well-tolerated, and how it affects long COVID symptoms. Researchers will give eligible participants up to 2 doses of the medication and monitor them closely with follow-up exams and lab tests.
Long COVID affects millions of people, causing persistent fatigue, cognitive problems, breathing difficulties, and other debilitating symptoms that can last months or years after a COVID-19 infection. This medication works by boosting certain immune cells, and researchers believe it may help the body recover and reduce long COVID symptoms.
You likely qualify if…
You likely don't qualify if…
You would receive up to 2 doses of the medication during the trial. You'll attend multiple follow-up visits for exams, blood tests, and other assessments to check your safety and how you're responding to the treatment. The entire study involves close monitoring by the research team to ensure the medication is well-tolerated and to track any changes in your symptoms.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
ImmunityBio, Inc.
Enrollment target
~20 participants
Started
November 2025
Primary completion
October 2026
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kayleigh Russell
ImmunityBio, Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.